Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling

Fig. 1

Simultaneous administration of pimecrolimus and hUCB-MSCs deteriorates therapeutic effects of MSCs against atopic dermatitis. AD was induced in NC/Nga mice by repetitive exposure to Df extract in the dorsal and ear regions for 3 weeks. Each group of mice was monitored and sacrificed on day 27 for further analysis. a Schematic of the experimental course of AD induction in mice. b Representative gross images of dorsal and ear lesions. c Clinical severity was assessed by scoring dryness, excoriation, erythema and edema. The Kruskal–Wallis test with Dunn’s post hoc test was used to assess the significance of differences in scoring index at day 27. N = 3–5 mice per group. n.s: not significant and *P < 0.05. The results are shown as the mean ± SD

Back to article page